Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

First International Summit on Interventional Pharmacoeconomics

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

David A. Hyman, MD, JD, on Inclusive Shared Savings

Peter Clark, MA, MD, FRCP: A Payer Perspective

Mar

Today In Oncology

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Related Videos

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

David A. Hyman, MD, JD, on Inclusive Shared Savings

Peter Clark, MA, MD, FRCP: A Payer Perspective

Stanford Names Leader for Drug Development and Precision Oncology

Neoadjuvant Sacituzumab Govitecan Plus Perioperative Pembrolizumab in Muscle-Invasive Bladder Cancer

Prostate Cancer Does Taking ARPIs and Anticoagulants Together Raise Risks

FDA Releases Updated Guidance on Biosimilar Development

SABCS 2025: High-Level Review of Select Data